Interest in and Preference for Long-acting Injectable Antiretroviral Therapy in the Era of Approved Cabotegravir/Rilpivirine Among Reproductive-aged Women in the US South

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2024 Jun 29

PMID 38943370

Authors

Lauren F Collins

Anandi N Sheth

Tina Tisdale

C Christina Mehta

Gaea Daniel

Daniel Westreich

Seble Kassaye

Elizabeth F Topper

Deborah Konkle-Parker

Aadia Rana

Maria L Alcaide

Morgan M Philbin

Affiliations

Soon will be listed here.

Abstract

Among 103 reproductive-aged women with human immunodeficiency virus (HIV) in the US South surveyed post-approval of long-acting injectable (LAI) cabotegravir/rilpivirine, nearly two-thirds reported willingness to try LAI antiretroviral therapy (ART). Most expressed preference for LAI over daily oral ART and had minimal concerns over potential LAI-ART use impacting reproductive health.

Citing Articles

Enhancing Hepatitis B Virus Vaccine Uptake and Immunity Through Long-Acting Antiretroviral Therapy Programmatic Synergy in the US South.

Ochieng E, Robinson V, Anderson E, Niles-Carnes L, Smith B, Armstrong W Open Forum Infect Dis. 2025; 12(3):ofaf096.

PMID: 40046888 PMC: 11879927. DOI: 10.1093/ofid/ofaf096.

References

van der Wekken-Pas L, Weiss F, Simon-Zuber C, Sebisch R, Wiese C, van Leeuwen E . Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV. Clin Infect Dis. 2024; 79(6):1468-1471. PMC: 11650856. DOI: 10.1093/cid/ciae242. View

Raiford J, Yuan X, Carree T, Beer L . Understanding Disparities in Antiretroviral Therapy Adherence and Sustained Viral Suppression Among Black, Hispanic/Latina, and White Women in the United States - Medical Monitoring Project, United States, 2015-2019. J Acquir Immune Defic Syndr. 2023; 93(5):413-421. PMC: 10524626. DOI: 10.1097/QAI.0000000000003214. View

Philbin M, Bergen S, Parish C, Kerrigan D, Kinnard E, Reed S . Long-Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most. AIDS Behav. 2021; 26(4):1260-1269. PMC: 8940643. DOI: 10.1007/s10461-021-03483-7. View

Patel P, Ford S, Baker M, Meyer C, Garside L, DAmico R . Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials. HIV Med. 2022; 24(5):568-579. DOI: 10.1111/hiv.13439. View

Barr E, Marshall L, Collins L, Godfrey C, St Vil N, Stockman J . Centring the health of women across the HIV research continuum. Lancet HIV. 2024; 11(3):e186-e194. PMC: 11301651. DOI: 10.1016/S2352-3018(24)00004-3. View

Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D . Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV. 2021; 8(4):e185-e196. DOI: 10.1016/S2352-3018(20)30340-4. View

Benning L, Mantsios A, Kerrigan D, Coleman J, Golub E, Blackstock O . Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy. BMC Womens Health. 2020; 20(1):152. PMC: 7382076. DOI: 10.1186/s12905-020-01011-8. View

Sheth A, Adimora A, Golub E, Kassaye S, Rana A, Westreich D . Study of Treatment and Reproductive Outcomes Among Reproductive-Age Women With HIV Infection in the Southern United States: Protocol for a Longitudinal Cohort Study. JMIR Res Protoc. 2021; 10(12):e30398. PMC: 8726043. DOI: 10.2196/30398. View

Coleman H, Fox J, Chilton D . The risks associated with stopping injectable antiretroviral treatment in women who are trying to conceive: a case series. AIDS. 2022; 36(8):1205-1206. DOI: 10.1097/QAD.0000000000003236. View

10.

McCrimmon T, Collins L, Pereyra M, Platamone C, Perez-Brumer A, Shaffer V . Likelihood of Trying Long-Acting Injectable Antiretroviral Therapy Among Women With HIV in Nine Sites Across the United States. J Acquir Immune Defic Syndr. 2024; 96(3):e23-e27. PMC: 11250912. DOI: 10.1097/QAI.0000000000003422. View

11.

Jaeger H, Overton E, Richmond G, Rizzardini G, Andrade-Villanueva J, Mngqibisa R . Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV. 2021; 8(11):e679-e689. DOI: 10.1016/S2352-3018(21)00185-5. View

12.

Beer L, Mattson C, Bradley H, Skarbinski J . Understanding Cross-Sectional Racial, Ethnic, and Gender Disparities in Antiretroviral Use and Viral Suppression Among HIV Patients in the United States. Medicine (Baltimore). 2016; 95(13):e3171. PMC: 4998540. DOI: 10.1097/MD.0000000000003171. View

13.

Meade C, Badell M, Hackett S, Mehta C, Haddad L, Camacho-Gonzalez A . HIV Care Continuum among Postpartum Women Living with HIV in Atlanta. Infect Dis Obstet Gynecol. 2019; 2019:8161495. PMC: 6393891. DOI: 10.1155/2019/8161495. View